210527 – Transgene BioInvent_BT001 IND_EN
Category: BT-001 (EN)
Transgene and BioInvent have enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors
20210301 – Transgene BT-001 FPI – EN
Transgene and BioInvent receive approval from ANSM to proceed with Phase I/IIa trial of anti-CTLA4-armed oncolytic virus BT-001 in solid tumors
20210119 – ANSM Approval BT-001 EN
Transgene and BioInvent receive CTA approval for Phase 1/2a trial of oncolytic virus BT-001 in solid tumors
20201221 – CTA Approval BT-001 – EN
Transgene and BioInvent present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
20201109 Transgene BioInvent_SITC BT001_EN
BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
Poster BT-001 M. Semmrich et al. SITC 2020 Download the poster here Poster Presentation
Transgene and BioInvent to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
20201015 – BT-001_SITC poster EN
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
AACR2020-BT-001 Jean-Baptiste Marchand et al. AACR 2020 Download the poster here Poster Presentation
Transgene’s and BioInvent’s BT-001 achieves outstanding tumor cure rates in preclinical models
20200622b – BT-001_AACR poster EN
Transgene presents promising new data from its next-generation immunotherapy platforms at AACR 2020
20200622a – Transgene PR AACR 3 posters
